The Medical Device Coordination Group (MDCG), an advisory body of the European Commission composed of the EU Member States` representatives and focused on the improvement of the medical devices regulatory framework, issued guidance documents for medical device manufacturers and notified bodies dedicated to the most important aspects of clinical evaluation related to the concept of equivalence. 

It is important to mention that due to the functions and role of the MDCG in the legislative process, the guidance does not implement binding rules and requirements. The provisions stated in the guidance should be used as best practices and serve as a basis for further improvement. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Scope of the MDCG Guidance

 

The existing regulatory framework is based on the Medical Device Regulation 2017/745 (MDR) stating that the manufacturer of a medical device subject to conformity assessment is allowed to make references to the clinical data related to an equivalent device. According to the aforementioned regulations, the acceptable sources of the clinical data include:

  • Clinical investigation(s) or other studies reported in scientific literature, of a device for which equivalence to the device in question can be demonstrated,
  • Reports published in the peer-reviewed scientific literature on other clinical experiences of either the device in question or a device for which equivalence to the device in question can be demonstrated. 

It is also important to mention that the European Commission has already issued guidance dedicated to certain aspects of the clinical evaluation under the Directives 93/42/EEC and 90/385/EEC – the directives constituting the basis of medical devices legislation before the implementation of the MDR. 

At the same time, the demonstration of equivalence does not substitute clinical evaluation that is mandatory for medical devices in the course of conformity assessment. The demonstration of equivalent is necessary to use clinical data related to the equivalent device for the purpose of confirming compliance with the general safety and performance requirements. 

In particular, the present MDCG guidance describes the way clinical data related to the device already placed on the market should be used for placing a CE mark. The document also highlights key points of the new regulatory framework to be introduced by the MDR. The scope of the guidance also covers certain products without an intended medical purpose. 

Medical Device Equivalence 

 

According to the regulations 2017/745, the demonstration of equivalence should be based on the most important characteristics, such as technical, biological, and clinical ones. First of all, the document outlines the differences in approach to equivalence under the regulatory frameworks provided by the MDR and MEDDEV 2.7/1 rev 4 respectively. 

In general, the requirements on technical characteristics provided by these two regulations are similar, except the following points:

  • In accordance with the MDR, the device should be used under similar conditions, while the MEDDEV 2.7/1 states that the device should be used under the same conditions;
  • The scope of the properties and specifications covered by the MDR also includes software algorithms. 

The concept of similar conditions states that the conditions of use should not be different significantly enough to impact safety and performance characteristics.  

According to the MDR, software algorithms used in the device the references are made to should be the same as ones used in the device in question. Thus, the clinical performance and intended purpose of the software should be the same, while there is no equivalence requirement regarding the software code. It is also important to mention that the software without an intended medical purpose actually falls outside the scope of this requirement since it does not significantly impact the safety of the performance of the device. 

The requirements regarding the biological characteristics differ substantially depending on the particular framework. According to the MDR, the device should use the same materials or substances for a similar kind and duration of contact and similar release characteristics of substances, including degradation products and leachables, while the MEDDEV does not contain the appropriate enhanced requirements. At the same time, the MEDDEV provides a list of exclusions that should not be applicable under the MDR. In particular, under the MDR, the materials contacting the human body should be the same for both devices. The MDCG guidance also refers to the different parts of the ISO 10993 standard (e.g. ISO 10993-1, ISO 10993-17, and ISO 10993-18) containing additional requirements on biocompatibility. 

The approach to the third group of characteristics, the clinical ones, also differs for both regulatory frameworks, namely:

  • The MDR indicates the requirement on the same clinical condition or purpose, while the MEDDEV states that the devices should have the same medical indications;
  • Under the MDR, the device should have the same kind of user, while the MEDDEV provides a broader indication, stating that the device should be used in a similar population (age, gender, anatomy, physiology, possibly other aspects).

For the purpose of this requirement, the user shall mean a healthcare professional or patient (user) using the device himself. This concept is used to determine the level of qualification and special knowledge reasonably necessary to use the device in a safe and efficient way. 

 

Demonstration of Equivalence

 

The approaches to the demonstration of equivalence used by both regulations are also different. According to the MDR, considerations of equivalence shall be based on proper scientific justification, while the MEDDEV does not contain the appropriate requirement. At the same time, the general approach to the considerations of equivalence based on the technical, biological, and clinical characteristics is the same for both regulations. It is also important to mention that in case of any modifications made to the device, such modifications should neither impact significantly the safety and performance of the device nor expose patients (user) to additional risks. 

The MDCG guidance explicitly states that the manufacturer of a medical device in question shall not make references to a product without an intended medical purpose when making claims regarding the equivalence. At the same time, it is allowed to make references to the several medical devices already placed on the market simultaneously, proving that each of the devices the manufacturer refers to meets the admissibility requirements regarding technical, biological, and clinical characteristics. Thus, it is not allowed to make references to the separate parts of medical devices – only to the device as a whole. The only exclusion from this rule relates to the systems of medical devices composed of several independent medical devices. 

According to the MDR, the manufacturer of a medical device in question should justify the level of clinical equivalence sufficient to confirm compliance with the applicable safety and performance requirements. Thus, all characteristics should be subject to rigorous investigation. In particular, the manufacturer shall provide a detailed comparison to the device it refers to, highlighting both similarities and differences between the two devices. 

Summarizing the information provided hereabove, the MDCG guidance on clinical evaluation and equivalence describes the way the manufacturer shall make references to similar medical devices already present on the market when applying for placing a CE mark. The document outlines the particular requirements the reference device should meet in order to be suitable for making references to the clinical data related to that device in the course of conformity assessment. 

How Can RegDesk Help?

RegDesk is a next-generation web-based software for medical device and IVD companies. Our cutting-edge platform uses machine learning to provide regulatory intelligence, application preparation, submission and approvals management globally. Our clients also have access to our network of over 4000 compliance experts worldwide to obtain verification on critical questions. Applications that normally take 6 months to prepare can now be prepared within 6 days using RegDesk Dash(TM). Global expansion has never been this simple.

Sources:

https://ec.europa.eu/docsroom/documents/40903